$275 Million is the total value of Affinity Asset Advisors, LLC's 55 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.06% | – |
| IMVT | Exit | IMMUNOVANT INCcall | $0 | – | -30,000 | -100.0% | -0.07% | – |
| ASLN | Exit | ASLAN PHARMACEUTICALS LTDads | $0 | – | -250,000 | -100.0% | -0.11% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -12,500 | -100.0% | -0.12% | – |
| SKINW | Exit | THE BEAUTY HEALTH COMPANY*w exp 05/04/2026 | $0 | – | -34,400 | -100.0% | -0.13% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -125,000 | -100.0% | -0.16% | – |
| Exit | TANGO THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.16% | – | |
| IPHA | Exit | INNATE PHARMA S Asponsored ads | $0 | – | -125,000 | -100.0% | -0.20% | – |
| ACHL | Exit | ACHILLES THERAPEUTICS PLCsponsored ads | $0 | – | -100,000 | -100.0% | -0.20% | – |
| LUNG | Exit | PULMONX CORP | $0 | – | -25,000 | -100.0% | -0.23% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -7,500 | -100.0% | -0.26% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -20,000 | -100.0% | -0.27% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -111,400 | -100.0% | -0.27% | – |
| BLI | Exit | BERKELEY LTS INC | $0 | – | -55,000 | -100.0% | -0.27% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -38,814 | -100.0% | -0.28% | – |
| PCVX | Exit | VAXCYTE INC | $0 | – | -50,000 | -100.0% | -0.32% | – |
| SDGR | Exit | SCHRODINGER INC | $0 | – | -25,000 | -100.0% | -0.34% | – |
| LSAQ | Exit | LIFESCI ACQUISITION II CORP | $0 | – | -150,000 | -100.0% | -0.37% | – |
| BFLY | Exit | BUTTERFLY NETWORK INC | $0 | – | -150,000 | -100.0% | -0.40% | – |
| MREO | Exit | MEREO BIOPHARMA GROUP PLCads | $0 | – | -650,000 | -100.0% | -0.40% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -15,000 | -100.0% | -0.42% | – |
| AFIB | Exit | ACUTUS MED INC | $0 | – | -200,000 | -100.0% | -0.45% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -10,000 | -100.0% | -0.47% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -75,000 | -100.0% | -0.48% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.50% | – |
| Exit | GOSSAMER BIO INCnote 5.000% 6/0 | $0 | – | -2,000,000 | -100.0% | -0.53% | – | |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.89% | – | |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -75,000 | -100.0% | -0.91% | – |
| EDIT | Exit | EDITAS MEDICINE INCput | $0 | – | -100,000 | -100.0% | -1.04% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -35,910 | -100.0% | -1.45% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -35,350 | -100.0% | -1.54% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -750,000 | -100.0% | -1.89% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -100,000 | -100.0% | -10.84% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -700,000 | -100.0% | -22.22% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-07 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.